×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LGND – ligand pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LGND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/27
10:08 am
lgnd
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]
Medium
Report
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]
4/27
07:00 am
lgnd
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Low
Report
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
4/22
07:00 am
lgnd
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Low
Report
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
4/15
04:27 pm
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
4/14
11:10 am
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
4/14
07:00 am
lgnd
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Medium
Report
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
4/4
11:17 am
lgnd
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
Low
Report
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
3/30
08:11 pm
lgnd
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
Medium
Report
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
07:00 am
LGND
ligand pharmaceuticals incorporated
BEAT
Report
1.9%
ligand pharmaceuticals incorporated
11/6/2025
07:00 am
LGND
ligand pharmaceuticals incorporated
BEAT
Report
4.6%
ligand pharmaceuticals incorporated
8/7/2025
07:00 am
LGND
ligand pharmaceuticals incorporated
BEAT
Report
1.9%
ligand pharmaceuticals incorporated
5/8/2025
07:00 am
LGND
ligand pharmaceuticals incorporated
BEAT
Report
-2.5%
ligand pharmaceuticals incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/27
09:41 am
lgnd
Form DEFA14A LIGAND PHARMACEUTICALS
Medium
Report
Form DEFA14A LIGAND PHARMACEUTICALS
4/27
09:30 am
lgnd
Form 8-K LIGAND PHARMACEUTICALS For: Apr 27
Medium
Report
Form 8-K LIGAND PHARMACEUTICALS For: Apr 27
4/21
04:05 pm
lgnd
Form ARS LIGAND PHARMACEUTICALS For: Dec 31
Low
Report
Form ARS LIGAND PHARMACEUTICALS For: Dec 31
4/21
04:03 pm
lgnd
Form DEFA14A LIGAND PHARMACEUTICALS
Low
Report
Form DEFA14A LIGAND PHARMACEUTICALS
4/21
04:02 pm
lgnd
Form DEF 14A LIGAND PHARMACEUTICALS For: Dec 31
Low
Report
Form DEF 14A LIGAND PHARMACEUTICALS For: Dec 31
4/2
07:44 pm
lgnd
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: KOZARICH JOHN W
Low
Report
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: KOZARICH JOHN W
4/2
06:57 pm
lgnd
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: Reardon Andrew
Low
Report
Form 4 LIGAND PHARMACEUTICALS For: Apr 01 Filed by: Reardon Andrew
4/1
04:11 pm
lgnd
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
Low
Report
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
24.8%
11/8 Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol 7.1%
3/2 Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March 6.5%
9/12 Form 8-K LIGAND PHARMACEUTICALS For: Aug 27 6.3%
4/8 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at HC Wainwright from $237.00 to $229.00. 6.2%
4/6 Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call 5.7%
9/19 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $132.00 price target on the stock, up previously from $110.00. 5.5%
3/24 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating. 5.2%
6/3 Form 8-K LIGAND PHARMACEUTICALS For: May 31 4.3%
7/31 Form 4 LIGAND PHARMACEUTICALS For: Jul 31 Filed by: HIGGINS JOHN L 4.2%
11/8 Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol 7.1%
3/2 Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March 6.5%
9/12 Form 8-K LIGAND PHARMACEUTICALS For: Aug 27 6.3%
4/8 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at HC Wainwright from $237.00 to $229.00. 6.2%
4/6 Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call 5.7%
9/19 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $132.00 price target on the stock, up previously from $110.00. 5.5%
3/24 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating. 5.2%
6/3 Form 8-K LIGAND PHARMACEUTICALS For: May 31 4.3%
7/31 Form 4 LIGAND PHARMACEUTICALS For: Jul 31 Filed by: HIGGINS JOHN L 4.2%
TOP News Decliners
3/13
Form 4 LIGAND PHARMACEUTICALS For: Mar 13 Filed by: FOEHR MATTHEW W
-21.8%
7/30 Q2/2019 6/30/2019 EPS 0.680 ZacksConsensus 0.380 ActVsEst 0.300 - Beat -12.6%
2/27 Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: FOEHR MATTHEW W -9.5%
11/6 Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.6%
3/27 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.2%
8/5 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at Barclays PLC from $131.00 to $110.00. They now have an "equal weight" rating on the stock. -6.8%
3/10 Ligand Pharmaceuticals (LGND) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.4%
6/10 Form 8-K LIGAND PHARMACEUTICALS For: Jun 06 -4.7%
11/13 Form 4 LIGAND PHARMACEUTICALS For: Nov 12 Filed by: FOEHR MATTHEW W -4.7%
3/17 Ligand Pharmaceuticals (LGND) Presents At 32nd Annual ROTH Conference - Slideshow [Seeking Alpha] -4.7%
7/30 Q2/2019 6/30/2019 EPS 0.680 ZacksConsensus 0.380 ActVsEst 0.300 - Beat -12.6%
2/27 Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: FOEHR MATTHEW W -9.5%
11/6 Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.6%
3/27 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.2%
8/5 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at Barclays PLC from $131.00 to $110.00. They now have an "equal weight" rating on the stock. -6.8%
3/10 Ligand Pharmaceuticals (LGND) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.4%
6/10 Form 8-K LIGAND PHARMACEUTICALS For: Jun 06 -4.7%
11/13 Form 4 LIGAND PHARMACEUTICALS For: Nov 12 Filed by: FOEHR MATTHEW W -4.7%
3/17 Ligand Pharmaceuticals (LGND) Presents At 32nd Annual ROTH Conference - Slideshow [Seeking Alpha] -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: